LGALS1 and central nervous system cancer: Puchades et al. demonstrated that in vitro silencing of galectin-1 increased sensitivity of U87MG glioma cells to the topoisomerase inhibitor SN-38, and recombinant galectin-1 partially reversed this effect, suggesting that galectin-1 protects glioma cells via an extracellular mechanism [123].